NCCN, a not-for-profit alliance of 23 of the world’s leading cancer centers dedicated to improving the quality, effectiveness, and efficiency of cancer care, has appointed Gary Weyhmuller, MBA, as Executive Vice President and Chief Operating Officer (COO).
JNCCN – Journal of the National Comprehensive Cancer Network named Margaret A. Tempero, MD, UCSF Helen Diller Family Comprehensive Cancer Center, as the new Editor-in-Chief, succeeding Harold J. Burstein, MD, PhD, who served in the position for five years.
The NCCN Oncology Research Program (ORP) has established the NCCN Affiliate Research Consortium (ARC) to maximize collaboration between the NCCN Member Institutions and their affiliate research investigators.
The NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ will take place on March 13 – 15, 2014 in Hollywood, Florida; The 2014 conference features two expert roundtable discussions and clinical treatment updates for more than 15 disease types.
Mayo Clinic Cancer Center and Yale Cancer Center/Smilow Cancer Hospital have been named the newest NCCN Member Institutions; NCCN now has 25 Member Institutions serving patients throughout the United States.
NCCN’s opening roundtable focused on the child’s experience when a parent has cancer, noting that honest, age-appropriate communication about cancer, its treatment, and death are beneficial at any age.
The second roundtable of the NCCN 19th Annual Conference explored the Affordable Care Act (ACA) and the new-found risk that providers, payers, and patients are learning to navigate.
More than 1,300 oncology representatives attended the NCCN 19th Annual Conference, which featured presentations of the latest developments in the treatment of more than 15 cancer types, as well as two expert roundtable discussions.
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of nintedanib in colorectal and lung cancers at NCCN Member Institutions.
The National Comprehensive Cancer Network® (NCCN®) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.
The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
The third annual NCCN State Oncology Society Forum, held at the NCCN 19th Annual Conference, examining the evaluation of quality in oncology, the utilization of clinical guidelines and pathways, and the consequences with the Sunshine Act.
New NCCN Guidelines for Patients®: Breast Cancer Stages 0 – IV now available free-of-charge at NCCN.org/patients; NCCN Guidelines for Patients® are educational resources that offer patient-friendly treatment information.
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of volasertib in hematologic malignancies.
The NCCN Foundation® has awarded the fourth series of Young Investigator Awards to five young investigators from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
The NCCN Oncology Research Program (ORP) and Pfizer Independent Grants for Learning & Change have awarded six independent grants to implement quality improvement and health care professional education in renal cell carcinoma and hematologic malignancies.
NCCN has launched its Reimbursement Resource App, which offers patients, providers, case managers, and payers access to payment assistance and reimbursement programs for multiple cancer types; the app is available free of charge for Apple and Android mobile devices.
On July 10, 2014, NCCN will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program.
On August 16, 2014, NCCN will host the second of two free patient information webinars designed to allow patients and their caregivers the opportunity to listen to live expert discussions about non-small cell lung cancer.
The National Comprehensive Cancer Network® (NCCN®) will host its 9th Annual Congress: Hematologic Malignancies™ in New York, NY, September 19 – 20, 2014.
NCCN has published the 20th annual edition of its NCCN Guidelines® for Small Cell Lung Cancer, marking the first 20th edition of the eight original NCCN Guidelines published in November 1996.
NCCN is accepting original abstracts from investigators for consideration for the NCCN 20th Annual Conference General Poster Session; Submissions will be accepted from NCCN Member Institutions, academic institutions, teaching and community hospitals, or industry.
The NCCN ORP has awarded four research grants to investigate the effectiveness of nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.
As part of the company’s coverage policy development, Cigna is using the NCCN Guidelines® and the NCCN Compendium® as reference in appropriate choice for the treatment of people with cancer in the United States.
On November 3, 2014, NCCN will host its annual Patient Advocacy Summit: Patient Concerns in 2014 – Big Data, Access, and Palliative Care, at The National Press Club in Washington, DC.
NCCN has published the 20th annual editions of the NCCN Guidelines® for Colon and Rectal Cancers, two of the original eight NCCN Guidelines published in November 1996.
The integration of the NCCN Chemotherapy Order Templates (NCCN Templates®) into Epic allows for access to evidence-based treatment protocols based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Printed NCCN Guidelines for Patients® available for order on Amazon.com for Breast (Stages 0 – IV), Colon, and Pancreatic Cancers; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma.
NCCN has published the 20th annual edition of the NCCN Guidelines® for NSCLC, one of the eight original NCCN Guidelines published in November 1996.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Prostate Cancer, one of the eight original NCCN Guidelines published in November 1996.
The NCCN 3D Virtual Simulator Learning Platform allows users to walk through the continuum of care approach to colorectal cancer in a risk-free environment with increasingly complex clinical presentations.
A new collaboration between NCCN and Flatiron Health will provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.
A recent Stanford Cancer Institute study shows that adherence to the NCCN Guidelines® for Colon Cancer in an integrated health care setting improves outcomes in all patients, including minorities.
January 31, 2015 marks the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 25 academic cancer centers devoted to patient care, research, and education.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Breast Cancer, one of the original NCCN Guidelines published in November 1996.
Centers for Medicare & Medicaid Services encourages concordance to NCCN Guidelines for Medicare patients in order to achieve better care, smarter spending, and healthier people.
NCCN has published NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia (ALL), the newest addition to the library of NCCN Guidelines for Patients®.
Approximately 1,500 oncology stakeholders are expected to attend NCCN’s 20th Annual Conference: Advancing the Standard of Cancer Care™, March 12 – 14, 2015, in Hollywood, Florida.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Ovarian Cancer, one of the original NCCN Guidelines published in November 1996.
NCCN has published the 20th annual edition of the NCCN Guidelines® for Acute Myeloid Leukemia, one of the original NCCN Guidelines published in 1996.
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute has been named the newest NCCN Member Institution; NCCN now has 26 Member Institutions serving patients throughout the United States.
The second roundtable discussion of the NCCN 20th Annual Conference explored the concept of value in oncology decision-making, challenging the perceived definition of value and true quality for the patient.
Approximately 1,500 oncology representatives attended the NCCN 20th Annual Conference, which featured presentations of the latest developments in the treatment of more than 15 cancer types, as well as three expert roundtable discussions.
The fourth annual state oncology society forum, held in conjunction with NCCN’s 20th Annual Conference, examined accountable care, payment reform, and best practices from community oncologists.
The third and final roundtable of the NCCN 20th Annual Conference explored essential elements of clinical practice guidelines, as well as the historical development of the NCCN Guidelines®.
The NCCN Foundation® has awarded its fifth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
The NCCN Oncology Research Program (ORP) has received a $2-million grant from ImmunoGen, Inc. to facilitate preclinical and clinical research with mirvetuximab soravtansine for Folate Receptor Alpha-positive cancers at NCCN Member Institutions and their affiliate community hospitals.
The integration of the NCCN Chemotherapy Order Templates (NCCN Templates®) into the Flatiron Health OncoEMR® electronic health record will allow for access to evidence-based treatment protocols based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
The National Comprehensive Cancer Network® (NCCN®) will host Emerging Issues in Tissue Allocation, on June 8, 2015, at the National Press Club in Washington, DC.
NCCN and Pfizer will elicit grant proposals for quality improvement and education in metastatic breast cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right